ArticlePloS one2026
The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanosecond Pulsed Electric Field (nsPEF) is an intense electrical pulse technology with ultra-short duration (nanoseconds), capable of generating electric field intensities up to several kV/cm. By inducing irreversible electroporation for tumor tissue ablation, nsPEF triggers apoptosis in cancer cells, stimulates anti-tumor immune responses, and enhances exogenous gene transfection. As a primarily non-thermal technique, it offers advantages such as minimal tissue damage, high targeting efficiency, short treatment duration, and compatibility with other therapies. Currently demonstrating broad application potential in cancer treatment. Urothelial Bladder Carcinoma (UBC), accounting for over 90% of bladder cancers, originates from the transitional epithelium of the bladder's urothelium and represents the most common malignant tumor in the urinary system. Cisplatin (CDDP), a key chemotherapeutic agent for UBC, is particularly effective for recurrent or advanced-stage patients. However, repeated use often leads to drug resistance. This study investigates the cytotoxic effects of nsPEF on UBC cells and its inhibitory mechanisms against drug-resistant UBC. Through sustained gradient concentration induction of CDDP, we successfully established drug-resistant cell lines T24/CDDP and TCC/CDDP. After treatment with nsPEF on parental cell lines (T24, TCC) and their drug-resistant variants (T24/CDDP, TCC/CDDP), all cells exhibited time-and dose-dependent sensitivity. Western blot analysis revealed that the basal expression of γ-H2AX was significantly reduced in the drug-resistant cells (T24/CDDP, TCC/CDDP), while nsPEF treatment significantly upregulated its expression. In vivo experiments further demonstrated that nsPEF exhibited significant antitumor efficacy against tumor-bearing mice from T24/CDDP. Overall, nsPEF effectively induces apoptosis in T24, TCC, and their drug-resistant variants, with particularly potent effects on drug-resistant UBC cells. This enhanced effect may be attributed to nsPEF-induced more severe DNA damage in drug-resistant cells, as manifested by elevated γ-H2AX expression.. This study provides experimental evidence for applying nsPEF to overcome chemotherapy resistance in UBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.